Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid

Vogelstein, 1992, Carcinogens leave fingerprints, Nature, 355, 209, 10.1038/355209a0 Hollstein, 1991, p53 mutations in human cancers, Science, 253, 49, 10.1126/science.1905840 Giglia-Mari, 2003, TP53 mutations in human skin cancers, Hum. Mutat., 21, 217, 10.1002/humu.10179 Pfeifer, 2002, Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers, Oncogene, 21, 7435, 10.1038/sj.onc.1205803 Pfeifer, 2003, On the origin of G --> T transversions in lung cancer, Mutat. Res., 526, 39, 10.1016/S0027-5107(03)00013-7 DeMarini, 2001, Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions, Cancer Res., 61, 6679 Hussain, 2007, TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer, Oncogene, 26, 2166, 10.1038/sj.onc.1210279 Pleasance, 2010, A small-cell lung cancer genome with complex signatures of tobacco exposure, Nature, 463, 184, 10.1038/nature08629 Pleasance, 2010, A comprehensive catalogue of somatic mutations from a human cancer genome, Nature, 463, 191, 10.1038/nature08658 Petitjean, 2007, Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database, Hum. Mutat., 28, 622, 10.1002/humu.20495 Besaratinia, 2010, Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing, FASEB J., 24, 2612, 10.1096/fj.10-157263 Luo, 2001, Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool, Oncogene, 20, 320, 10.1038/sj.onc.1204080 Olivier, 2010, TP53 mutations in human cancers: origins, consequences, and clinical use, Cold Spring Harb. Perspect. Biol., 2, a001008, 10.1101/cshperspect.a001008 Petronic, 2000, Tumors of the upper urothelium and endemic nephropathy, 350 Lai, 2010, Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk, J. Natl. Cancer Inst., 102, 179, 10.1093/jnci/djp467 Yang, 2002, Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan, Urology, 59, 681, 10.1016/S0090-4295(02)01529-7 Chen, 2012, Aristolochic acid-associated urothelial cancer in Taiwan, Proc. Natl. Acad. Sci. U. S. A., 109, 8241, 10.1073/pnas.1119920109 Grollman, 2013, Aristolochic acid nephropathy: harbinger of a global iatrogenic disease, Environ. Mol. Mutagen., 54, 1, 10.1002/em.21756 Grollman, 2007, Aristolochic acid and the etiology of endemic (Balkan) nephropathy, Proc. Natl. Acad. Sci. U. S. A., 104, 12129, 10.1073/pnas.0701248104 Jelakovic, 2012, Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid, Kidney Int., 81, 559, 10.1038/ki.2011.371 Moriya, 2011, TP53 Mutational signature for aristolochic acid: an environmental carcinogen, Int. J. Cancer, 129, 1532, 10.1002/ijc.26077 Arlt, 2007, Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer, Carcinogenesis, 28, 2253, 10.1093/carcin/bgm082 De Broe, 2012, Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity aristolochic acid nephropathy, Kidney Int., 81, 513, 10.1038/ki.2011.428 Grollman, 2009, Aristolochic acid nephropathy: an environmental and iatrogenic disease, Adv. Mol. Tox., 3, 211, 10.1016/S1872-0854(09)00007-1 Olivier, 2012, Upper urinary tract urothelial cancers: where it is A:T, Nat. Rev. Cancer, 12, 503, 10.1038/nrc3311 Schetter, 2012, Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome, Proc. Natl. Acad. Sci. U. S. A., 109, 7955, 10.1073/pnas.1205457109 Djukanovic, 2003, Balkan endemic nephropathy, 588 Shibutani, 2007, Selective toxicity of aristolochic acids I and II, Drug Metab. Dispos., 35, 1217, 10.1124/dmd.107.014688 Hsieh, 2008, Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003, Chin Med., 3, 13, 10.1186/1749-8546-3-13 Nortier, 2000, Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi), N. Engl. J. Med., 342, 1686, 10.1056/NEJM200006083422301 Mengs, 1983, On the histopathogenesis of rat forestomach carcinoma caused by aristolochic acid, Arch. Toxicol., 52, 209, 10.1007/BF00333900 Mengs, 1988, Tumour induction in mice following exposure to aristolochic acid, Arch. Toxicol., 61, 504, 10.1007/BF00293699 Sidorenko, 2012, Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts, Nucleic Acids Res., 40, 2494, 10.1093/nar/gkr1095 Martinez, 2002, Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose, Nephrol. Dial. Transplant., 17, 408, 10.1093/ndt/17.3.408 Lai, 2010, Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study, Am. J. Kidney Dis., 55, 507, 10.1053/j.ajkd.2009.10.055 Grollman, 2007, Role of environmental toxins in endemic (Balkan) nephropathy. October 2006, Zagreb, Croatia, J Am. Soc. Nephrol., 18, 2817, 10.1681/ASN.2007050537 Hranjec, 2005, Endemic nephropathy: the case for chronic poisoning by aristolochia, Croat. Med. J., 46, 116 Ivic, 1969, Etiology of endemic nephropathy, Lijec. Vjesn., 91, 1273 Lord, 2004, DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy, Am. J. Kidney Dis., 43, e11, 10.1053/j.ajkd.2003.11.024 Sidorenko, 2012, Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts, Nucleic Acids Res., 40, 2494, 10.1093/nar/gkr1095 Attaluri, 2010, DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells, Nucleic Acids Res., 38, 339, 10.1093/nar/gkp815 Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc. Natl. Acad. Sci. U. S. A., 100, 8424, 10.1073/pnas.1431692100 Marcel, 2009, p53 isoforms – a conspiracy to kidnap p53 tumor suppressor activity?, Cell. Mol. Life Sci., 66, 391, 10.1007/s00018-008-8336-3 Wang, 2012, ACB-PCR measurement of H-ras codon 61 CAA-->CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues, Environ. Mol. Mutagen., 53, 495, 10.1002/em.21710 McDaniel, 2012, Mutagenicity and DNA adduct formation by aristolochic acid in the spleen of Big Blue(R) rats, Environ. Mol. Mutagen., 53, 358, 10.1002/em.21696 Xing, 2012, Comparison of the mutagenicity of aristolochic acid I and aristolochic acid II in the gpt delta transgenic mouse kidney, Mutat. Res., 743, 52, 10.1016/j.mrgentox.2011.12.021 Hergenhahn, 2004, p53 designer genes for the modern mouse, Cell Cycle, 3, 738, 10.4161/cc.3.6.890 Liu, 2004, Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene, Proc. Natl. Acad. Sci. U. S. A., 101, 2963, 10.1073/pnas.0308607101 vom Brocke, 2006, MEF immortalization to investigate the ins and outs of mutagenesis, Carcinogenesis, 27, 2141, 10.1093/carcin/bgl101 Nedelko, 2009, TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours, Int. J. Cancer, 124, 987, 10.1002/ijc.24006 Reinbold, 2008, Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72, Oncogene, 27, 2788, 10.1038/sj.onc.1210932 Whibley, 2010, Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence, J. Biol. Chem., 285, 11326, 10.1074/jbc.M109.064444 Hollstein, 1994, p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride- exposed factory workers, Carcinogenesis, 15, 1, 10.1093/carcin/15.1.1 Weihrauch, 2000, p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chloride, Cancer, 88, 1030, 10.1002/(SICI)1097-0142(20000301)88:5<1030::AID-CNCR12>3.0.CO;2-4 Rothberg, 2011, An integrated semiconductor device enabling non-optical genome sequencing, Nature, 475, 348, 10.1038/nature10242 Rosenquist, 2011, Genetic loci that affect aristolochic acid-induced nephrotoxicity in the mouse, Am. J. Physiol. Renal Physiol., 300, F1360, 10.1152/ajprenal.00716.2010 Stiborova, 2008, Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy, Mutat. Res., 658, 55, 10.1016/j.mrrev.2007.07.003